Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Bio_Products_Laboratory_(BPL)
|
| gptkbp:CEO |
gptkb:Paolo_Marcucci
|
| gptkbp:founded |
2001
|
| gptkbp:foundedBy |
gptkb:Marcucci_family
|
| gptkbp:headquartersLocation |
gptkb:Lucca,_Italy
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kedrion Biopharma
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:numberOfEmployees |
over 2,600
|
| gptkbp:operatesIn |
gptkb:Germany
gptkb:Hungary gptkb:Italy gptkb:Mexico gptkb:Turkey gptkb:United_States |
| gptkbp:parentCompany |
gptkb:Permira
gptkb:F.I.S._–_Fabbrica_Italiana_Sintetici |
| gptkbp:product |
albumin
immunoglobulins coagulation factors hyperimmune plasma products |
| gptkbp:revenue |
over €800 million (2022)
|
| gptkbp:specializesIn |
plasma-derived products
|
| gptkbp:stockExchange |
not publicly listed
|
| gptkbp:website |
https://www.kedrion.com/
|
| gptkbp:bfsParent |
gptkb:WinRho_SDF
|
| gptkbp:bfsLayer |
7
|